FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer
Oncology Research · 2026
DOI: 10.32604/or.2025.072592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Myeong Ryeo Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gachon Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon, 21936, Republic of Korea. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Drug Resistance, Neoplasm, Histone-Lysine N-Methyltransferase. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gachon Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon, 21936, Republic of Korea.
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China.
Zitieren
APA
Kim, M. R., Lee, J. R., Zhang, X., & Jeong, K. W. (2026). FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer. Oncology Research. https://doi.org/10.32604/or.2025.072592
Vancouver
Kim MR, Lee JR, Zhang X, Jeong KW. FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer. Oncology Research. 2026. doi:10.32604/or.2025.072592
BibTeX
@article{Kim2026,
author = {Kim, Myeong Ryeo and Lee, Jae Rim and Zhang, Xiaohan and Jeong, Kwang Won},
title = {FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2025.072592}
}
EUVIMED